Literature DB >> 923630

Plasma renin concentration in essential hypertension during beta-adrenergic blockade and vasodilator therapy.

E B Pedersen, H J Kornerup.   

Abstract

Plasma renin concentration (PRC) was measured in 46 patients with essential hypertension before and after treatment for 4 weeks with alprenolol 600-1200 mg daily. In 27 of these patients PRC was measured after 4 weeks of combined treatment with alprenolol and hydralizine. During alprenolol treatment PRC and blood pressure were reduced, but the changes were not correlated. Alprenolol treatment caused similar blood pressure reductions in patients with high and low PRC, and the antihypertensive efficacy of beta-adrenergic blocking agents could not be predicted from the pretreatment PRC. When beta-adrenergic blockade was supplemented with hydralazine, blood pressure was further reduced, but PRC remained unchanged. Although a causal relationship between blood pressure reduction and suppression of renin, production might exist at low doses of beta-adrenergic blocking agents, the present study did not indicate such a relationship when higher doses were used. It was shown that alprenolol inhibited the increase in PRC usually induced by hydralazine, but it is not known whether this was important for the effectiveness of the fall in blood pressure produced by hydralazine.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 923630     DOI: 10.1007/bf00645128

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  11 in total

1.  Beta-adrenergic blockade in diuretic-treated patients with essential hypertension.

Authors:  E L Bravo; R C Tarazi; H P Dustan
Journal:  N Engl J Med       Date:  1975-01-09       Impact factor: 91.245

2.  Effect of alprenolol on blood pressure and plasma renin activity in hypertensive patients.

Authors:  J Castenfors; H Johnsson; L Orö
Journal:  Acta Med Scand       Date:  1973-03

3.  Plasma renin concentration measured by use of radioimmunoassay for angiotensin I.

Authors:  J Giese; M Jörgensen; M D Nielsen; J O Lund; O Munck
Journal:  Scand J Clin Lab Invest       Date:  1970-12       Impact factor: 1.713

4.  Cardiovascular effects of intracerebroventricular d-, l- and dl-propranolol in the conscious rabbit.

Authors:  J L Reid; P J Lewis; M G Myers; C T Dollery
Journal:  J Pharmacol Exp Ther       Date:  1974-02       Impact factor: 4.030

5.  Observation on the mechanism of renin release by hydralazine in hypertensive patients.

Authors:  H Ueda; Y Kaneko; T Takeda; T Ikeda; S Yagi
Journal:  Circ Res       Date:  1970-10       Impact factor: 17.367

6.  Propranolol inhibition of renin secretion. A specific approach to diagnosis and treatment of renin-dependent hypertensive diseases.

Authors:  F R Bühler; J H Laragh; L Baer; E D Vaughan; H R Brunner
Journal:  N Engl J Med       Date:  1972-12-14       Impact factor: 91.245

7.  Beta-adrenergic blockade in essential hypertension. Effects of propranolol on hemodynamic parameters and plasma renin activity.

Authors:  L Hansson
Journal:  Acta Med Scand Suppl       Date:  1973

8.  Central cardiovascular effects of intracerebroventricular propranolol.

Authors:  R K Srivastava; V K Kulshrestha; N Singh; K P Bhargava
Journal:  Eur J Pharmacol       Date:  1973-02       Impact factor: 4.432

9.  Altered renin release and propranolol potentiation of vasodilatory drug hypotension.

Authors:  W A Pettinger; K Keeton
Journal:  J Clin Invest       Date:  1975-02       Impact factor: 14.808

10.  Treatment of hypertension with propranolol.

Authors:  B N Prichard; P M Gillam
Journal:  Br Med J       Date:  1969-01-04
View more
  5 in total

Review 1.  The second Lilly Prize Lecture, University of Newcastle, July 1977. beta-Adrenergic receptor blockade in hypertension, past, present and future.

Authors:  B N Prichard
Journal:  Br J Clin Pharmacol       Date:  1978-05       Impact factor: 4.335

2.  Propranolol and beta-adrenergic receptor blocking drugs in the treatment of hypertension.

Authors:  B N Prichard
Journal:  Br J Clin Pharmacol       Date:  1982-01       Impact factor: 4.335

3.  Effect of oral labetalol on plasma catecholamines, renin and aldosterone in patients with severe arterial hypertension.

Authors:  H J Kornerup; E B Pedersen; N J Christensen; A Pedersen; G Pedersen
Journal:  Eur J Clin Pharmacol       Date:  1979-11       Impact factor: 2.953

Review 4.  Drug treatment of hypertension.

Authors:  B N Prichard
Journal:  Drugs       Date:  1988       Impact factor: 9.546

5.  Correlation between propranolol in plasma and urine, renin-aldosterone system and blood pressure in essential hypertension.

Authors:  E B Pedersen; H J Kornerup; O L Pedersen; F Andreasen; P Bjerregaard
Journal:  Eur J Clin Pharmacol       Date:  1981       Impact factor: 2.953

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.